cyclophosphamide + docetaxel + epirubicin + tucidinostat

This is a combination regimen consisting of four agents: - Cyclophosphamide, an alkylating agent that crosslinks DNA, leading to cell death. - Docetaxel, a taxane-class chemotherapeutic that stabilizes microtubules and inhibits their depolymerization, disrupting mitosis. - Epirubicin, an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, resulting in inhibition of DNA replication and repair. - Tucidinostat (also known as chidamide or HBI-8000), a benzamide class histone deacetylase inhibitor (HDACi) that selectively inhibits class I HDAC1/2/3 and class IIb HDAC10. Tucidinostat modulates gene expression by promoting histone acetylation and chromatin relaxation; it has antineoplastic activity through epigenetic modulation[1][4][5][6]. This combination is investigational for cancer therapy. Each component targets different mechanisms involved in tumor growth or survival.